Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 5:35:10175.
doi: 10.3389/ti.2022.10175. eCollection 2022.

Reduced Rates of Post-Transplant Recurrent Hepatocellular Carcinoma in Non-Alcoholic Steatohepatitis: A Propensity Score Matched Analysis

Ryan Lamm  1 , Peter J Altshuler  1 , Keyur Patel  1 , Osama Shaheen  1 , Angel Paulo Amante  1 , Jesse Civan  2 , Warren Maley  1 , Adam Frank  1 , Carlo Ramirez  1 , Jaime Glorioso  1 , Ashesh Shah  1 , Hien Dang  1 , Adam S Bodzin  1
Affiliations

Reduced Rates of Post-Transplant Recurrent Hepatocellular Carcinoma in Non-Alcoholic Steatohepatitis: A Propensity Score Matched Analysis

Ryan Lamm et al. Transpl Int. .

Abstract

Non-alcoholic steatohepatitis (NASH)-related hepatocellular carcinoma (HCC) has become the second leading cause of HCC-related liver transplantation in the United States. This study investigated post-transplant recurrence and survival for patients transplanted for NASH-related HCC compared to non-NASH HCC etiologies. Retrospective review of the United Network for Organ Sharing (UNOS) Organ Procurement and Transplantation Network (OPTN) database identified 7,461 patients with HCC-1,405 with underlying NASH and 6,086 with non-NASH underlying diseases. After propensity score matching (PSM) to account for patient- and tumor-related confounders 1,175 remained in each group. Primary outcomes assessed were recurrence rate and recurrence-free survival. Recurrent malignancy at 5 years post-transplant was lower in NASH compared to non-NASH patients (5.80 vs. 9.41%, p = 0.01). Recurrence-free survival, however, was similar at 5 years between groups. Patients with NASH-related HCC were less likely to have post-transplant recurrence than their non-NASH counterparts, although recurrence-free survival was similar at 5 years.

Keywords: Organ Procurement and Transplantation Network; United Network for Organ Sharing; hepatocellular carcinoma; non-alcoholic steatohepatitis; recurrence.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Study design. NASH transplant recipients with HCC were first compared to non-NASH recipients with HCC. These patients were then propensity matched and further compared. Additional analysis was performed on the unmatched populations to compare with post-transplant HCC recurrence and post-recurrence survival between NASH and non-NASH populations.
FIGURE 2
FIGURE 2
Cumulative incidence of post-transplant HCC recurrence (A) and Kaplan-Meier curves comparing survival (B) in NASH vs PSM non-NASH patients.
FIGURE 3
FIGURE 3
Kaplan-Meier curves comparing survival following recurrence in NASH vs. non-NASH patients.
See this image and copyright information in PMC

References

    1. Kim E, Viatour P. Hepatocellular Carcinoma: Old Friends and New Tricks. Exp Mol Med (2020) 52(12):1898–907. 10.1038/s12276-020-00527-1 - DOI - PMC - PubMed
    1. Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, Duseja A, et al. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clin Gastroenterol Hepatol (2019) 17(4):748–55. 10.1016/j.cgh.2018.05.057 - DOI - PubMed
    1. Bobolts LR. Hepatocellular Carcinoma: Considerations for Managed Care Professionals. Am J Manag Care (2020) 26(10 Suppl. l):S220–S226. 10.37765/ajmc.2020.88513 - DOI - PubMed
    1. Patel K, Lamm R, Altshuler P, Dang H, Shah AP. Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy. Int J Mol Sci (2020) 21(18):6757. 10.3390/ijms21186757 - DOI - PMC - PubMed
    1. Beal EW, Tumin D, Kabir A, Moris D, Zhang X-F, Chakedis J, et al. Trends in the Mortality of Hepatocellular Carcinoma in the United States. J Gastrointest Surg (2017) 21(12):2033–8. 10.1007/s11605-017-3526-7 - DOI - PubMed

MeSH terms